Legacy Healthcare

We are pleased to announce that Legacy Healthcare founder & CEO Saad Harti will be attending the Dermatology Summit in San Francisco on 12 January 2025. The Derm Summit has become a leading forum for the industry to update on and support innovation in dermatology.

Pleased to have our Founder and CEO, Saad Harti, attending the 43rd annual JP Morgan Healthcare Conference next month in San Francisco.  Legacy Healthcare a Swiss biotech with a global presence in Switzerland, the US, and Japan, is pioneering botanical drugs. CINAINU is the proof-of-concept of our unique expertise in developing safe, effective prescription drugs from plant extracts to better treat complex chronic diseases. The company’s first product candidate, CINAINU, has demonstrated strong safety and efficacy in a phase 2/3 study involving patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it, especially children. Lots of opportunities for strategic discussions. If you are a potential investor or partner interested in exploring this dynamic space, please don't hesitate to reach out, let’s meet!

Welcome on-board (litteraly ;-)) Peter!

This September, we at Legacy Healthcare stand in solidarity with the 147 million individuals worldwide impacted by Alopecia Areata - a deeply challenging autoimmune condition that causes unpredictable hair loss on the scalp, face, and body. Alopecia areata can profoundly affect quality of life, particularly in children, where onset often occurs between ages 5 and 10. Legacy Healthcare, is committed to developing safe and effective botanical treatments to address unmet needs in inflammatory immune disorders such as Alopecia Areata. Image Credit: Canada Alopecia Areata Foundation

We are pleased to share the the Journal of the American Academy of Dermatology (JAAP) has published an online version of a review article that describes patient preferences for the treatment of alopecia areata. The article highlghts that patients generally preferred topical treatments over oral or injectable options and that their top preferences include hair regrowth efficacy, a favorable safety profile with minimal systemic risks, and convenient administration methods. These findings align well with our strategy and the targeted product profile of CINAINU, our topical botanical drug under development of r children and adolscents with moderate to severa alopecia areata. To access the full review article by Carmichael AR, Lovell KK, Prieto K, Feldman SR, Pichardo RO, entitled “Patient preferences in the treatment of alopecia areata: a review of the literature”, JAAD Reviews (2024), please click on the following link: https://lnkd.in/d5vTQujB

We are pleased to announce that Peter R. Nicholson has been appointed to Legacy Healthcare’s Board of Directors to serve as an independent director. A San Francisco, California native, Mr. Nicholson currently resides in Switzerland and is Managing Director of ALTEKA, a boutique strategic advisory firm serving the biopharmaceutical industry.  He was previously Senior Vice President of Global Business Development for Dermavant Sciences, an Organon company.  Before that, he served as Vice President of Strategy and Business Development for Galderma.  He held similar roles for Mentor Worldwide LLC (Johnson & Johnson) and INAMED Corporation (Allergan Aesthetics, an AbbVie Company).  He was co-founder and CEO of Eurofins Genomics Blue Heron.  While working at Amgen, he worked in product development and then joined the product licensing team, responsible for creating the company’s corporate venture capital program. Peter joins Saad Harti, Founder and Chairman, as well as Geert Cauwenbergh and Johanne Barthelet-Harti, both of whom are co-founders as well as Board members.  

We are pleased to share the the Journal of the American Academy of Dermatology (JAAP) has published an online version of a review article that describes patient preferences for the treatment of alopecia areata. The article highlghts that patients generally preferred topical treatments over oral or injectable options and that their top preferences include hair regrowth efficacy, a favorable safety profile with minimal systemic risks, and convenient administration methods. These findings align well with our strategy and the targeted product profile of CINAINU, our topical botanical drug under development of r children and adolscents with moderate to severa alopecia areata. To access the full review article by Carmichael AR, Lovell KK, Prieto K, Feldman SR, Pichardo RO, entitled “Patient preferences in the treatment of alopecia areata: a review of the literature”, JAAD Reviews (2024), please click on the following link: https://lnkd.in/d5vTQujB

This September, we at Legacy Healthcare stand in solidarity with the 147 million individuals worldwide impacted by Alopecia Areata - a deeply challenging autoimmune condition that causes unpredictable hair loss on the scalp, face, and body. Alopecia areata can profoundly affect quality of life, particularly in children, where onset often occurs between ages 5 and 10. Legacy Healthcare, is committed to developing safe and effective botanical treatments to address unmet needs in inflammatory immune disorders such as Alopecia Areata. Image Credit: Canada Alopecia Areata Foundation

We are pleased to announce that data from our RAAINBOW phase 2/3 will be presented by Sergio Vañó Galván at the 23rd annual congress of the Academia Española de Dermatologia and Venerologia (AEDV) taking place in Madrid, 2 May 2024. For more information, please visit: https://lnkd.in/e--X6GFn The AEDV Congress is a premier event in the field of dermatology, bringing together academics, practitioners, and healthcare professionals to discuss advancements in skin health and related diseases.

We are pleased to share that Legacy Healthcare was featured today, 13 November 2024, in Bilan Magazine, in an article written by Ghislaine Bloch. The full article can be accessed at: https://lnkd.in/dZgvKUVQ